- Home
- CRIS vs MTVA Comparison
CRIS vs MTVA Comparison
Compare CRIS & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- MTVA
- Stock Information
- Founded
- CRIS 2000
- MTVA 2014
- Country
- CRIS United States
- MTVA United States
- Employees
- CRIS 33
- MTVA N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- MTVA
- Sector
- CRIS Health Care
- MTVA
- Exchange
- CRIS Nasdaq
- MTVA NYSE
- Market Cap
- CRIS 13.5M
- MTVA 13.6M
- IPO Year
- CRIS 2000
- MTVA N/A
- Fundamental
- Price
- CRIS $1.50
- MTVA $0.81
- Analyst Decision
- CRIS Strong Buy
- MTVA Strong Buy
- Analyst Count
- CRIS 3
- MTVA 1
- Target Price
- CRIS $21.00
- MTVA $12.00
- AVG Volume (30 Days)
- CRIS 102.7K
- MTVA 1.4M
- Earning Date
- CRIS 05-06-2025
- MTVA 05-08-2025
- Dividend Yield
- CRIS N/A
- MTVA N/A
- EPS Growth
- CRIS N/A
- MTVA N/A
- EPS
- CRIS N/A
- MTVA N/A
- Revenue
- CRIS $10,908,000.00
- MTVA N/A
- Revenue This Year
- CRIS $2.33
- MTVA N/A
- Revenue Next Year
- CRIS $9.78
- MTVA N/A
- P/E Ratio
- CRIS N/A
- MTVA N/A
- Revenue Growth
- CRIS 8.83
- MTVA N/A
- 52 Week Low
- CRIS $1.02
- MTVA $0.71
- 52 Week High
- CRIS $16.99
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- CRIS 37.70
- MTVA N/A
- Support Level
- CRIS $1.06
- MTVA N/A
- Resistance Level
- CRIS $1.30
- MTVA N/A
- Average True Range (ATR)
- CRIS 0.15
- MTVA 0.00
- MACD
- CRIS 0.07
- MTVA 0.00
- Stochastic Oscillator
- CRIS 70.59
- MTVA 0.00
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.